Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on April 30, 2025
Altamira Therapeutics (OTCQB: CYTOF), a company focused on RNA delivery technology development for targets beyond the liver, has scheduled its Full Year 2024 Financial Results and Business Update Call for April 30, 2025, at 8:00 am ET.
The presentation will feature prepared remarks from Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda. The call will be conducted in listen-only mode, with replay access available through the webcast link after the live event.
Altamira Therapeutics (OTCQB: CYTOF), una società specializzata nello sviluppo di tecnologie per la consegna di RNA a bersagli oltre il fegato, ha programmato la sua Presentazione dei Risultati Finanziari Completi per l'anno 2024 e Aggiornamento Aziendale per il 30 aprile 2025, alle 8:00 ET.
La presentazione includerà interventi preparati di Thomas Meyer, Fondatore, Presidente e CEO, e di Covadonga Pañeda, COO. La chiamata sarà in modalità solo ascolto, con la possibilità di riascolto tramite il link webcast disponibile dopo l'evento in diretta.
Altamira Therapeutics (OTCQB: CYTOF), una empresa centrada en el desarrollo de tecnología para la entrega de ARN dirigida a objetivos más allá del hígado, ha programado su Conferencia de Resultados Financieros Anuales 2024 y Actualización Comercial para el 30 de abril de 2025 a las 8:00 am ET.
La presentación incluirá comentarios preparados de Thomas Meyer, Fundador, Presidente y CEO, y Covadonga Pañeda, COO. La llamada se realizará en modo solo escucha, con acceso a la repetición disponible a través del enlace del webcast después del evento en vivo.
Altamira Therapeutics (OTCQB: CYTOF)는 간을 넘어선 표적을 위한 RNA 전달 기술 개발에 주력하는 회사로, 2024 회계연도 전체 재무 결과 및 사업 업데이트 컨퍼런스 콜을 2025년 4월 30일 오전 8시(동부시간)에 예정하고 있습니다.
발표에는 창립자 겸 회장 겸 CEO인 토마스 마이어와 COO 코바동가 파녜다의 준비된 발언이 포함됩니다. 콜은 청취 전용 모드로 진행되며, 생중계 후 웹캐스트 링크를 통해 다시 듣기 이용이 가능합니다.
Altamira Therapeutics (OTCQB : CYTOF), une entreprise spécialisée dans le développement de technologies de livraison d’ARN ciblant au-delà du foie, a programmé sa conférence sur les résultats financiers annuels 2024 et mise à jour commerciale pour le 30 avril 2025 à 8h00 ET.
La présentation comprendra des interventions préparées de Thomas Meyer, fondateur, président et PDG et de Covadonga Pañeda, directrice des opérations. L’appel se déroulera en mode écoute seule, avec un accès au replay disponible via le lien du webcast après l’événement en direct.
Altamira Therapeutics (OTCQB: CYTOF), ein Unternehmen, das sich auf die Entwicklung von RNA-Liefertechnologien für Ziele außerhalb der Leber spezialisiert hat, hat seinen Finanzergebnisbericht für das Gesamtjahr 2024 und Geschäftsupdate-Anruf für den 30. April 2025 um 8:00 Uhr ET angesetzt.
Die Präsentation umfasst vorbereitete Ausführungen von Gründer, Vorsitzender und CEO Thomas Meyer sowie COO Covadonga Pañeda. Der Anruf wird im Nur-Zuhören-Modus durchgeführt, mit der Möglichkeit, die Aufzeichnung über den Webcast-Link nach der Live-Veranstaltung abzurufen.
- None.
- None.
Hamilton, Bermuda, April 25, 2025 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB: CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it will host its Full Year 2024 Financial Results and Business Update Call on Wednesday, April 30, 2025. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks.
Webcast Access:
- Event: Altamira Therapeutics Full Year 2024 Financial Results and Business Update Call
- Date: Wednesday, April 30, 2025
- Time: 8:00 am ET
- Webcast URL: https://edge.media-server.com/mmc/p/7t3h98aw
Registration for Call:
https://register-conf.media-server.com/register/BI95acee4618c44d05a56b78125b22638d
- Click on the call link and complete the online registration form.
- Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
- Select a method for joining the call.
- Dial-In: A dial in number and unique PIN are displayed to connect directly from your phone.
- Call Me: Enter your phone number and click “Call Me” for an immediate callback from the system. The call will come from a US number.
The call will be in listen-only mode.
A replay of the call will be available after the live event and accessible through the webcast link:
https://edge.media-server.com/mmc/p/7t3h98aw
About Altamira Therapeutics
Altamira Therapeutics (OTCQB:CYTOF) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a
Investor Contact
Hear@altamiratherapeutics.com
FAQ
When is Altamira Therapeutics (CYTOF) reporting its Full Year 2024 financial results?
How can investors access Altamira Therapeutics' (CYTOF) earnings call?
Who will be presenting at Altamira Therapeutics' (CYTOF) 2024 earnings call?
Will there be a replay available for Altamira Therapeutics' (CYTOF) earnings call?
